---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-22-000053"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:28:08.118815+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas Q3 net loss widens to $66.2M; cash at $1.28B; on track for Phase 3 starts

## Summary
- Net loss of $66.2M for Q3 2022 vs $46.8M in Q3 2021, driven by higher R&D and G&A costs.
- Cash, cash equivalents and marketable securities were $1,276.2M as of Sept 30, 2022, sufficient beyond 2024.
- R&D expenses nearly doubled to $77.5M, reflecting investment in platform and ER/AR programs.
- On track to initiate two Phase 3 trials for ARV-471 in metastatic breast cancer by end of 2022.
- Revenue from Pfizer collaboration drove revenues to $30.3M from $9.3M year-over-year.

## SEC filing metadata
- accession: 0001655759-22-000053
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/0001655759-22-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/arvn-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-22-000053
- JSON: https://secwatch.observer/filing/0001655759-22-000053.json
- Plain text: https://secwatch.observer/filing/0001655759-22-000053.txt

## Key facts
- Earnings Releases
  ARVINAS, INC. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/0001655759-22-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.